Active Pharmaceutical Ingredient Market

Active Pharmaceutical Ingredient Market to Witness a Rise of US$ 225.2 Bn 2016 –
An active pharmaceutical ingredient market is used in a finished pharmaceutical product
(FPP), intended to carry certain pharmacological actions or otherwise have a direct effect in
the diagnosis, cure, treatment, mitigation or prevention of various diseases, or in some cases
in restoring, correcting or modifying human physiological functions. Sales of
pharmaceutical ingredient are on the rise due to a substantial increase in high-potency API
(HPAPI) and peptide API manufacturing. A new study conducted by Persistence Market
Research reveals that the US$ 151.9 Bn global active pharmaceutical ingredient market will
grow to US$ 158.3 Bn by 2017 end, reflecting a Y-o-Y growth rate of 4.2%. This market is
estimated to further increase to US$ 225.2 Bn, expanding at a CAGR of 4.5% over the
forecast period (2016 – 2025)
According to the report, small molecule API type segment holds promising investment
opportunities for market participants on account of the numerous off-patent events incurred
in the last five years coupled with a strong penetration of small scale manufacturers in Asia.
On the basis region, APAC’s API market was valued at US$ 61.4 Bn in 2016 and is
projected to witness the highest CAGR of 5.1 % during the forecast period to reach a
valuation of US$ 95.6 Bn. This is primarily owing to the leadership of China and India in
SMEs as well as their strong distribution network in overseas markets especially in US,
South Africa, and Europe.
Asian pharmaceuticals CMOs are competing on the basis of cost and timeline for API
manufacturing and are attracting U.S.-based pharmaceuticals companies that are willing to
outsource manufacturing requirements. Meanwhile, Europe is projected to be the second
fastest growing market for API and is expected to reach US$ 42.5 Bn by 2025-end.
Manufacturers in Europe are prioritizing high-quality standards, advanced manufacturing
installations, and high purity of intermediates (API).
Johnson Matthey, Siegfried, Almac, PolyPeptide Laboratories, AmbioPharm, Inc., Corden
Pharma, Pepscan, BCN peptide, Provence Technologies Groups, SennChemicals AG, Avecia
OligoMedicines, Santaris Pharma - acquired by Roche in 2014, ST Pharm Oligo Center,
Cepia Sanofi, Biospring, Pfizer CenterSource, Symbiotec Pharma Lab Pvt. Ltd., Gadea
Grupo Farmacéutico, STEROID S.p.A., Dolder AG, Dalton Pharma Services, FarmaBios
Spa, Dextra Laboratories Limited, GlycoSyn, Inalco Pharma, Sussex Research, Pfanstiehl,
Inc., Noramco, Inc., Johnson Matthey, Siegfried, Rhodes Technologies, Ash Stevens,
Fermion (public), FARMHISPANIA GROUP, Olon SpA, Lonza Group are some of the
leading companies operating in the global active pharmaceutical ingredient market.
Browse Complete Report @
Currently, many of the pharmaceutical companies are focused on outsourcing of API
manufacturing to avoid large capital investments in setting up of API manufacturing
facilities. This has accelerated the demand for CMOs in API manufacturing industry, which
is dominated by small to medium manufacturers.

Sales of pharmaceutical ingredient are on the rise due to a substantial increase in high-potency API (HPAPI) and peptide API manufacturing.